News | October 01, 2021
Merck to acquire Acceleron for US $ 11.5 billion
The acquisition complements and strengthens Merck’s cardiovascular pipeline
The acquisition complements and strengthens Merck’s cardiovascular pipeline
CuraTeQ Biologics is on track for filing a second oncology biosimilar
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
The recommendation is based on positive results from the pivotal Phase 3 CheckMate -649 trial in which Opdivo plus chemotherapy demonstrated superior overall survival versus chemotherapy
In the final analysis of Phase 3 COVE study data, SPIKEVAX showed 93% efficacy, with the efficacy remaining durable through six months after the administration of the second dose
Data show the vaccine regimen induced neutralising antibody responses in nearly all participating adults and children 21 days after the second dose. Adults receiving booster shots two years after the initial vaccination regimen showed strong immune responses
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
The medicine is now approved for eight indications across five different types of cancer in China.
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
Subscribe To Our Newsletter & Stay Updated
